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Abstract
Background: We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1
vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV
sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was
to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand.
Methodology/Principal Findings: MVA-CMDR or placebo was administered intra-muscularly (IM; 10
7 or 10
8 pfu) or
intradermally (ID; 10
6 or 10
7 pfu) at months 0, 1 and 3, to 48 healthy volunteers at low risk for HIV-1 infection. Twelve
volunteers in each dosage group were randomized to receive MVA-CMDR or placebo (10:2). Volunteers were actively
monitored for local and systemic reactogenicity and adverse events post vaccination. Cellular immunogenicity was assessed
by a validated IFNc Elispot assay, an intracellular cytokine staining assay, lymphocyte proliferation and a
51Cr-release assay.
Humoral immunogenicity was assessed by ADCC for gp120 and binding antibody ELISAs for gp120 and p24. MVA-CMDR
was safe and well tolerated with no vaccine related serious adverse events. Cell-mediated immune responses were: (i)
moderate in magnitude (median IFNc Elispot of 78 SFC/10
6 PBMC at 10
8 pfu IM), but high in response rate (70%
51Cr-release
positive; 90% Elispot positive; 100% ICS positive, at 10
8 pfu IM); (ii) predominantly HIV Env-specific CD4
+ T cells, with a high
proliferative capacity and durable for at least 6 months (100% LPA response rate by the IM route); (iv) dose- and route-
dependent with 10
8 pfu IM being the most immunogenic treatment. Binding antibodies against gp120 and p24 were
detectable in all vaccination groups with ADCC capacity detectable at the highest dose (40% positive at 10
8 pfu IM).
Conclusions/Significance: MVA-CMDR delivered both intramuscularly and intradermally was safe, well-tolerated and
elicited durable cell-mediated and humoral immune responses.
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Introduction
Globally, an estimated 33.4 million people currently live with
HIV/AIDS and in 2008 alone, an estimated 2.7 million new
infections occurred [1]. Controlling the global HIV pandemic will
require a successful AIDS vaccine [2,3,4]. HIV vaccine develop-
ment was invigorated recently by the modest level of protective
efficacy observed in the low incident Thai heterosexual population
in the ALVAC-HIV/AIDSVAX B/E Phase III trial (RV144) [5].
Though the correlates of protection for RV144 remain under
active investigation, attempts to improve upon the current levels of
protection afforded by the prime-boost strategy used in RV144 are
underway. In the absence of an immune correlate, HIV vaccine
development is currently directed towards the quantitative and
qualitative improvement of vaccine-induced responses through the
use of novel vectors alone, or in prime-boost configurations [2,4].
The inclusion of ALVAC, a poxvirus-based vector, as a
component of the Thai Phase III trial suggests that improved
poxvirus vectors may be effective components of a realistic strategy
for vaccination against HIV infection.
One such promising attenuated poxvirus vector is modified
vaccinia Ankara (MVA). The potential of MVA as a safe and
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use during the smallpox eradication campaign in Germany where
over 120, 000 people were immunized without adverse effects
[6,7]. We report here a phase I safety and immunogenicity study
with a recombinant MVA-HIV vaccine expressing env/gag/pol
inserts derived from a CRF01_AE HIV-1 isolate from Chiang
Mai, Thailand, referred to here as MVA-CMDR (Chiang Mai
Double Recombinant). The construction details and pre-clinical
testing of this vaccine were published earlier [8]. MVA-CMDR
has been used as a heterologous boost at the Karolinska Institute,
Stockholm, Sweden and the Muhumbili University, Dar es
Salaam, Tanzania in previous multigenic and multiclade DNA-
prime/MVA-boost trials [9]. This phase I trial was conducted in
the US and Thailand focusing on dose escalation and route
comparisons of MVA-CMDR alone for the induction of cellular
and humoral immunogenicity in a vaccinia naı ¨ve population.
Materials and Methods
Study vaccine candidate
The MVA-CMDR was developed through collaboration
between the Laboratory of Viral Diseases (LVD)/National
Institute of Allergy and Infectious Diseases (NIAID) and the
Walter Reed Army Instiutite of Research (WRAIR)/US Military
HIV Research Program (MHRP) [8]. This multigenic vaccine
contains env/gag/pol inserts derived from CRF01_AE isolates from
Chiang Mai (CM), Thailand (HIV-1 CM235 env/CM240 gag/pol)
[10]. The product was produced and vialed under Good
Manufacturing Practice (GMP) at the WRAIR Pilot Bioproduc-
tion Facility (Forest Glen, Silver Spring, MD). The placebo
formulation was PBS with 7.5% lactose, pH7.4 and was identical
to the vaccine diluent.
Ethics statement, protocol authorization and regulatory
approval
The clinical trial protocol and all related documents were
approved by the following independent Institutional Review
Boards (IRBs): Division of Human Subject Protection, Walter
Reed Army Institute of Research; Ethical Review Committee for
Research in Human Subjects, Ministry of Public Health, Thai-
land; and Siriraj Institutional Review Broad, Faculty of Medicine,
Siriraj Hospital Mahidol University. The MVA-CMDR vaccine
product was evaluated in an IRB approved phase I study (RV158)
under WRAIR Protocol #1143. The study was registered with
www.clinicaltrials.gov, NCT00376090, and was conducted under
FDA-IND #12267 by the MHRP with the sponsorship of the
Office of the Surgeon General, Department of the Army, U.S.
Army Medical Materiel Development Activity (USAMMDA). The
study was conducted in accordance with the International
Conference on Harmonization, Good Clinical Practice guidelines
(ICH-GCP). All volunteers provided written informed consent
following discussion and counseling by the clinical study team
prior to enrollment and before any trial related procedures were
performed. The protocol for this trial and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocol S1.
Study design, vaccination regimen and recruitment
RV158 was conducted in Rockville, MD (MHRP Vaccine
Research Clinic) and in Bangkok, Thailand (Siriraj Hospital and
AFRIMS Clinical Trial Center). A total of 48 healthy, HIV-
negative, volunteers (18–49 years of age) were enrolled and
randomized to receive vaccine or placebo (10:2 per group). As
shown in Table 1, subjects were vaccinated intradermally (ID)
with either 10
6 or 10
7 plaque-forming units (pfu) of MVA-CMDR
(0.1 ml ID into the volar aspect of the forearm), or intramuscularly
(IM) with either 10
7 or 10
8 pfu (1 ml IM into the deltoid muscle).
The vaccines were administered at 0, 1 and 3 months for a total of
3 doses. The low dose Part A was conducted in the US to assess
safety and then Part B enrollment was split equally between the
US and Thailand sites.
Safety assessment and clinical laboratory evaluations
Eligibility was assessed over two visits (V1, V2). Eligible
volunteers were healthy, aged 18–49 years, HIV uninfected,
vaccinia naı ¨ve by serology and absence of physical evidence of
variolation or history of smallpox vaccination, and exhibited a
normal baseline electrocardiogram (ECG). Eligible, consenting
volunteers were enrolled and randomized to the different Groups:
1, 2, 3 or 4. They were block randomized within each group to
receive vaccine versus placebo (5:1 ratio). Volunteers were
observed in the clinic for 45 minutes after vaccination for early
post-injection reactions. During the observation period the
volunteer was taught how to complete a 6-day diary card for
any symptoms that might develop later. Within 24–48 hours post-
vaccination, volunteers received a phone call inquiring of adverse
reactions. Volunteers returned to the clinic two weeks post-
vaccination for a safety visit. This safety visit included solicitation
and review of adverse events, physical examination, ECG, and
blood for safety labs and immunogenicity studies. Two other
immunogenicity and associated follow-up visits for laboratory
results completed the trial schedule of 11 visits over a 12-month
period (9 month follow up post-vaccination).
HIV testing strategy
HIV testing was conducted day -90, 42, 98, and 252 using
Genetic Systems rLAV HIV-1 Enzyme Immunoasssay (EIA)(Bio-
Rad Laboratories, Hercules, CA), Genetic Systems HIV-1
Western Blot (Bio-Rad Laboratories) and the Amplicor HIV-1
RNA Test version 1.5 (Roche Diagnostics, Indianapolis, IN). All
Table 1. RV158 Study Design.
Part Group Randomization (Vaccine:Placebo) Dose/Route Schedule (months)**
PART A I* 10:2 10
7 pfu IM 0, 1, 3
(Low Dose) II 10:2 10
6 pfu ID 0, 1, 3
PART B III 10:2 10
8 pfu IM 0, 1, 3
(High Dose) IV* 10:2 10
7 pfu ID 0, 1, 3
*Route comparison groups receiving the same dose.
**All participants followed for 6 months after final vaccination.
doi:10.1371/journal.pone.0013983.t001
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were used to determine HIV infection status regardless of serology.
Test results were reported to the clinic staff as either ‘‘HIV
positive’’ or ‘‘HIV negative’’ since vaccine induced sero-reactivity
(VISR) to in vivo expressed vaccine antigens may lead to false-
positive HIV EIA and/or WB results and thus unblind staff to a
volunteer’s allocation (placebo or vaccine). Pre- and post-test HIV
counseling was performed at each visit.
Vaccinia exposure testing
Pre-vaccination sera were sent to V-Bio (St. Louis, MO) for
Vaccinia ELISA testing. The enzyme-linked immunosorbent assay
(ELISA) for vaccinia measures the level of vaccinia specific
antibody (IgG) in serum samples. The immunoenzymatic method
allows quantification of the virus specific antibody based on a
capture technique and subsequent color development measure-
ment by a spectrophotometer. The vaccinia IgG ELISA procedure
has been described previously and was modified as described [11].
Briefly, plates were coated with vaccinia antigen or negative
(mock-infected) cell culture lysate. Serial 2-fold dilutions of sera
were placed on both antigen-coated and mock-antigen coated
wells and incubated for two-hours at 37uC. After washing
horseradish peroxidase-conjugated anti-human IgG was added
to the plate followed by a two hour incubation at 37uC. After the
incubation period, the plates were washed and ABTS substrate
(Kirkegaard and Perry, Gaithersburg, MD) was added. Following
a 30-minute incubation at room temperature, stopping solution
(1%SDS) was added to the plates and the plates were read at 405/
492nm dual wavelength. Linear regression plots were prepared
and endpoint titers were determined based on an optical density
(OD) cut-off of 0.30 using UnitWin software.
Cellular Immunogenicity Assessment
Blood Collection. Peripheral blood mononuclear cells
(PBMC) for cellular immunogenicity assays were isolated from
whole blood collected in acid-citrate dextrose anti-coagulant using
standard procedures [12]. PBMC were either used fresh or
cryopreserved in RPMI media containing 20% fetal calf serum
and 10% dimethyl sulphoxide (DMSO) in the vapor phase of
liquid nitrogen or electric freezers (Revco) at #2130uC. All
PBMC processing was undertaken within 6 hours of blood
collection, and post-thaw PBMC viability was greater than 80%
for all samples tested.
Chromium (
51Cr)-release cytotoxic T lymphocyte (CTL)
assay. A standard chromium-release assay for CTL function
was performed. Effector cells were generated following a 2-week in
vitro stimulation co-culture of 16610
6 freshly isolated PBMC and
4610
6 PBMC infected with 5 pfu/cell of MVA-CMDR. The
culture was supplemented with 3.3 mg/ml of rIL-7 at the time of
initiation and was further supplemented with 20 U/ml of rIL-2
after 1 week. Target cells were autologous EBV-transformed B
cells (TBC) infected overnight with single recombinant MVA
constructs expressing either CM240 Gag/Pol or CM235 Env
(matching the MVA-CMDR insert sequences) and loaded with
51Cr sodium chromate. Lytic activity of the effector cells was
determined at E:T ratios of 50:1 and 25:1, with CD4 or CD8
dependence verified using immunomagnetic bead depletion.
Specificity of the response for the insert sequences was further
verified using cold target quenching with MVAp581 infected TBC
(30:1 cold:hot target cells) of the vector-specific responses. A
positive response was defined as $10% specific lysis for at least
one E:T ratio and at least a 50% reduction of lytic actvity using
immunomagnetic bead depletion. Vector-specific responses were
verified by the requirement of at least 50% quenching of lysis by
cold target addition. All reported data are based upon CD8-
dependence of the responses. CD4-dependent responses were rare,
and no difference between vaccine and placebo groups was
observed (data not shown).
Interferon-gamma (IFNc) Elispot assay. A validated IFNc
Elispot assay was performed using cryopreserved PBMC and pools
of synthetic peptides (15-mers overlapping by 11 amino aicds, of
.80% purity), or direct addition of MVA passage 581 (whole virus
at 5 pfu/cell) to determine the anti-insert and anti-vector
responses, respectively. Staphylococcal enterotoxin B (SEB) was
used as a positive control. Peptides for stimulation were
synthesized by New England Peptides (Gardner, MA) and
Sigma-Aldrich (St. Louis, MO) and pooled in a quality-
controlled laboratory. Briefly, 2610
5 PBMC were added to each
well of a Millipore MAIP Elispot plate that was pre-coated with
anti-IFNc mAb 1-D1K (Mabtech-AB, Sweden) and incubated
with the various stimuli for 18–20 hours. The presence of spot
forming cells was determined by detection with anti-IFNc mAb 7-
B6-1 (Mabtech-AB, Sweden) and color development using the
VectorStain kit 2-hour incubation. All tests were performed in
triplicate and the negative control performed in replicates of six
wells. Determination of a positive Elispot value derived from
validation of the assay and required the following criteria to be
met: 1) the spot forming cell (SFC) count of the ‘‘media only’’ wells
(3–4 per plate) was ,10 SFC/10
6 PBMCs; 2) the mean
background SFC count (PBMC only) had to be ,100 SFC/10
6
PBMCs; 3) the SFC count for the peptide pool wells was.27
SFC/10
6 PBMCs; and 4) the mean SFC count was .4 times the
mean background SFC count. Applying these criteria to 49 pre-
immunization samples tested with each of the three peptide pools
representing Gag, Pol and Env, yielded a false positive rate of
,1% (1/147 positive responses).
Tritiated (
3H)-thymidine antigen-specific lymphocyte
proliferation assay (LPA). The proliferative responses of
volunteer PBMC were measured by incubating 1610
5 cells per
well in 96-well U-bottom polystyrene plates with serial dilutions
(200 and 100 ng/ml) of Whole aldrithiol-2 Inactivated Virus
isolates CM235 (CM235WIV) and MN (MNWIV) (courtesy of Jeff
Lifson, NCI Frederick, MD), serial dilutions (5 and 1 mg/ml) of
TH023 gp140 (a modified soluble form of gp160, courtesy of
Sanofi-Pasteur) and serial dilutions (5 and 1 mg/ml) of LAI p24
(ABL Inc., Kensington, MD). To measure the lymphoproliferative
response to the MVA vector psoralen-inactivated vaccinia virus
Lister strain (Advanced Biotechnologies, Columbia, MD) was used
(1 mg/ml final). Tetanus Toxoid (TT) (Staten Serum Institute,
Copenhagen, Denmark) was used at 5 mg/ml as a recall antigen
control, and in a separate plate PBMC were cultured with control
mitogens: 2 mg/ml of PHA, 1.25 mg/ml of pokeweed mitogen and
20 mg/ml of concanavalin A (Sigma-Aldrich, St Louis, MO, USA).
After 3 days of incubation with mitogens and 6 days with the
antigens, cells were pulsed with 1 mCi/well of [
3H]-thymidine for
6 hr then harvested, counted and assessed for [
3H]-thymidine
incorporation. The data are expressed as a lymphocyte stimulation
index (LSI=(PBMC cpm with antigen)/(PBMC cpm with
medium)), to define antigen specificity. Individuals were
designated as responders to a given antigen if the LSI in
response to that antigen $5.
Multi-functional flow cytometry (MFC) assay.
Cryopreserved PBMC were thawed, washed and resuspended in
RPMI1640 with v/v 10% NHS and then co-incubated for 16–
20 hrs in the presence of peptide pools (1 mg/peptide/ml)
representing Gag, Pol or Env (MVA-CMDR insert vaccine
matched), the positive control SEB (10 ng/ml) or 5 pfu/cell of
MVA (passage 581, MVA vector-backbone). Anti-CD107a-FITC
Phase I HIV Vaccine Study
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the assay mix at set-up, while the protein transport inhibitors
Monensin (GolgiStop, BD Pharmingen) and Brefeldin A (Sigma-
Aldrich) were added 2 hours after set-up for the peptide and SEB
stimulations, and 6 hours after assay set-up for the MVA
stimulation. The following day, plates were washed, stained with
Aqua Live/Dead (Invitrogen Inc.), washed and resuspended in
FACSwash buffer (0.5% BSA, 0.1% azide), followed by surface
staining with anti-CD14/CD19-Alexa700 (BD Pharmingen), and
then simultaneous surface/intracellular staining with anti-CD4-
ECD (Coulter), anti-IFNc-PB (eBioscience), anti-TNFa-PE-Cy7
and anti-MIP1b-PE (BD Pharmingen), anti-CD3-APC-H7, anti-
CD8-PerCPCy5.5, and anti-IL2-APC (BD Biosciences). Cells were
acquired on a custom built BD LSR II cytometer (Becton
Dickenson, San Jose, CA). At least 250,000 total events were
acquired in the lymphocyte gate and the data analyzed using the
following software packages: FlowJo Version 8 (Treestar Inc.,
Ashland, OR, USA), and PESTLE and SPICE (courtesy Mario
Roederer, Vaccine Research Center, NIH, USA) software. The
peptides used for this assay were synthesized and pooled by JPT
Inc. Peptide pools consisted of 16-mers overlapping by 11 amino
acids matched to the CRF01_AE sequences encoded in the
vaccine, and spanned all gene-products. Each gene-product was
represented in a single peptide pool. A positive response was
defined as $0.025% gated positive cells and the test antigen
response exceeding the un-stimulated control by .3 times.
Whole Blood ICS. Both sites used a standard protocol and
results from the two sites were comparable. Whole blood was lysed
and stimulated according to a protocol developed on the basis of
previous reported data [13]. CM235WIV and a Gag peptide pool
that matched the vaccine were used as stimuli together with SEB
and the CD8-restricted Cytomegalovirus/Epstein-Barr virus/
Influenza virus (CEF) peptide pool [14] as positive controls. For
the high dose groups a pool of HIV-1 92THO23 (a CRF01_AE
isolate similar to CM 235) Env peptides (15-mers overlapping by
11 amino acids) was used as a stimulus. Un-stimulated cells were
included in the panel and represent the background. Cells were
then stained with the following panel: CD3-APC, CD4-FITC,
CD8-PerCpCy5.5, IL2-PE and IFNc-PE (combined). At least
60,000 CD3
+ events were collected on a FACScaliber and data
were analyzed using FlowJo software (Version 8). A positive
response was defined as $0.05% gated positive cells and the test
antigen response exceeding the unstimulated control by $3 times.
Humoral Immunogenicity Assessment
ELISA measurement of serum IgG binding to Gag p24 or
Env gp120. Proteins dissolved in phosphate-buffered saline
(PBS; pH 7.4) containing 0.01% thimerosal were coated onto
96-well Immulon 2 microtiter plates (Fisher Scientific, Pittsburgh,
PA, USA) and incubated overnight at 4uC. The protein
concentrations were as follows: Baculovirus-derived p24 at
0.5 mg/ml (ImmunoDiagnostics, Inc., Woburn, MA, USA), E.
coli-derived p24 at 0.5 mg/ml (generously provided by Venigala
Rao, Catholic University of America, Washington, DC, USA) or
Baculovirus-derived gp120 from clade CRF01_AE strain CM243,
at 0.25 mg/ml (Protein Sciences Corp. Meridian, CT, USA). Both
sources of p24 were from the clade B IIIB strain. After coating,
plates were washed three times with wash buffer (PBS with 0.1%
Tween 20 [pH 7.4]) and incubated for 1 hour at 37uC with two-
fold dilutions of serum diluted in serum wash buffer with 5% skim
milk (pH 7.4). The plates were then washed and horseradish
peroxidase-conjugated goat anti-human IgG diluted 1:16,000 in
serum diluent (Goat anti-human IgG: Kirkgaard & Perry,
Gaithersburg, MD, USA) was added for 1 hour at 37uC. The
plates were again washed and substrate (p24-ABTS, gp120-TMB;
Kirkgaard & Perry) was added for 30 min. Plates were read by
spectrophotometry at 405nm, 490nm reference filter (for ABTS
substrate) or at 410nm, 570nm reference filter (for TMB substrate)
to determine OD values. For all assays, the endpoint titers were
determined as the reciprocal of the highest serum dilution yielding
OD values that were greater than the negative control cut-off
value. The cut-off value was calculated as two times the average
OD (+2 SD) for HIV-negative normal human sera. Each sample
was run by two independent operators and the concordant values
(values that were within 4-fold of each other) were averaged to
yield the reported reciprocal titer. Quantitative results are
presented as geometric mean titers (GMT) for each group.
Antibody dependent cellular cytotoxicity (ADCC)
assay. The assay has been described in detail elsewhere
[15,16]. Briefly, PBMC from Thai HIV seronegative donors
were used as effector cells.
51Cr labeled CEM.Nk
r cells coated with
either CRF01_AE gp120 (CM243) or subtype B gp120 (MN) were
used as target cells at an E:T ratio of 100:1 in the presence of
plasma at 10-fold dilutions ranging from 1:100 to 1:1000000. Each
dilution was performed in triplicate. Effectors and targets were
incubated for 6 hours at 37uC. HIV-specific ADCC activity was
calculated for each serum dilution as % Specific lysis (SL): [Mean
cpm (HIV antigen)- Mean cpm (spon)/Mean cpm (max)-Mean
cpm (spon)] where the max and spon were the mean cpm released
by the target cells in the presence of 10% SDS or media,
respectively. Inter-assay variability was reduced by converting the
SL to relative lysis (RL): [%SL (max) post-vaccination - %SL (max)
pre-vaccination/%SL (max) positive control-%SL (max) negative
control)] where % SL (max) represents the maximum % SL
obtained from a participant’s post-vaccination serum over the
range of plasma dilutions, % SL pre-vaccination (max) represents
%SL at the same dilution as the post-vaccination sample, %SL
(max) positive control represents maximum %SL obtained from
the positive plasma control at one dilution and %SL (max)
negative control represents %SL at the same dilution as the
positive plasma control. Additionally, we compared groups using a
dichotomous outcome (positive or negative) based on the 90
th
percentile of the % RL for the placebo group for each
corresponding antigen as a cut-off for a positive response.
Data Analysis
All laboratory staff remained blinded as to placebo and vaccine
status of the samples during assay performance and analysis. Data
were analyzed from all participants, including those not complet-
ing the vaccination series and assessed statistically using non-
parametric statistical tests where appropriate. For the qualitative
assessment of response rates, proportions were compared in 2 by 2
contingency tables using Fisher’s exact test. The x
2 trend test was
used to investigate trends in increasing response and event rates in
the dosage groups. Quantitative comparisons between two groups
were performed using the Mann-Whitney U test (for unmatched
pairs) or Wilcoxon signed rank test (for matched pairs). For
comparisons of multiple groups the Kruskal-Wallis test was
performed with correction using Dunn’s multiple comparison test.
A p-value of ,0.05 was considered statistically significant.
Results
Enrollment, participant flow and demographics
As shown in the trial participant Consort diagram (Figure 1A),
179 subjects (155 US, 24 Thai) were screened for this study, of
whom, 51 (39 US, 12 Thai) were eligible enrollment. Due to the
open enrollment nature of the study we were able to enroll three
Phase I HIV Vaccine Study
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of the study prior to completion of the enrollment phase. The last
study visit was completed on 25 November 2008. Demographics
were similar between vaccine and placebo recipients. Mean
volunteer age was between 30–32 years with a predominately male
(66%) and African-American (61%) representation at the US site.
The Thai sites only enrolled Thai citizens. Most potential
volunteers aged .35 or over were excluded because of pre-
existing vaccinia immunity. Five individuals did not complete the
vaccination series in the vaccine group; four were in the ID group
Figure 1. Consort clinical trial participant flow diagram (panel A). Chronological schematic diagram showing all pre-enrollment, vaccination
and blood collection visits for RV158 (panel B). Immunogenicity testing visits 3, 6, 8, 9 and 10 correspond to days 0, 42, 98, 168 and 252 post-
vaccination initiation respectively.
doi:10.1371/journal.pone.0013983.g001
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Reasons for discontinuation of vaccination after a first dose
included the development of pruritis without rash, social stigma
from community, non-cardiac chest pain, after missed visits due to
elective kidney donation and flu-like symptoms. All volunteers
missing vaccination were followed up for safety and did well for
the remainder of the study. All volunteers in the placebo groups
completed the vaccination series (8/8). Figure 1B shows the study
timeline, highlighting the screening visits, the vaccination schedule
and follow-up visits for safety and immunomonitoring.
Safety and tolerability
The vaccine had an excellent safety profile. No related serious
adverse events occurred during the study. There were no deaths,
pregnancies or HIV infections during the study. The highest grade
AE experienced was a Grade 2. The vaccine arm of the study had
more local and systemic adverse events than the placebo arm.
Vaccine recipients in the high-dose ID (Group 4) reported more
local reactogenicity such as injection site tenderness, pain,
erythema, induration, swelling, and itching than the low-dose
IM group (Group 1). Most systemic reactions were of mild or
moderate severity, such as fatigue, headache, nausea, myalgia,
arthralgia, diarrhea, pruritis, loss of appetite and chills. There was
no statistical difference in the rate of systemic reactions among the
treatment groups. There was one individual who reported chest
pain associated with fatigue, dizziness, and headache. An
evaluation, which included cardiac enzymes and ECG, determine
the chest pain was non-cardiac in nature. One volunteer in Group
4 had a temperature of 38.7uC (Grade 2) that resolved in 24 hours.
There was no pattern of laboratory abnormalities and no
significant differences in laboratory evaluations between vaccine
and placebo recipients. Figure 2 summarizes the reported adverse
events for systemic and local reactogenicity.
Cellular Immunogenicity
Chromium (
51Cr) release CTL assay. Results of the
chromium release CTL assay are shown in Table 2. Responses
were assessed pre-vaccination and at all 4 post-vaccination
immunogenicity visits. Cumulative CD8-dependent CTL
responses against any HIV gene product were detected in 63%
(24/38) of all vaccinees and were predominantly Env-directed (22
Env versus 8 Gag/Pol responders). Overall, the response rate to
Env was significantly greater than Gag/Pol (p=0.001; Fisher’s
exact test) with only 2 vaccinees exhibiting Gag/Pol responses in
the absence of an Env response. There was no statistically
significant dose- or route-dependence of the HIV-specific
responses with 56–70% of subjects responding in any group of
the trial. Env responses were predominant in all groups (50–67%)
with Gag/Pol responses observed most frequently in the high-dose
IM group (40%). While the Gag/Pol responses did show a
significant trend (p=0.047; x
2 trend test) towards a higher positive
rate with increasing dose of vaccine (Table 2), these data should
be viewed with caution given the low overall rate of Gag/Pol CTL
responses. No positive responses were detected pre-vaccination,
and one placebo was positive at a single time for an Env response
(1/7). Anti-vector (MVA) CD8-dependent CTL responses were
detected in 73% (28/38) of all vaccine recipients, with no vector-
specific responses detected pre-immunization or in the placebo
group. A route-dependence of the anti-vector response was evident
with both IM groups exhibiting a significantly higher response rate
(100% for high-dose; 80% for low-dose) than either ID group
(56% for both doses) (p=0.027, Fisher’s exact test). No pre-
vaccination or placebo recipient CD8-dependent positive CTL
responses were detected against the vector (see supplementary
Figure S1).
IFNc Elispot assay. Table 3 summarizes the IFNc Elispot
results. Responses were assessed at one pre-vaccination time-point
and all four post-vaccination immunogenicity visits. IFNc Elispot
responses against insert gene products were detected in 55% (22/
40) of all vaccinees at least once post-vaccination. While there was
a predominance of Env-directed Elispot responses (20 Env, 13
Gag and 2 Pol responders), the difference between Env and Gag
response rates was not statistically significant (Fisher’s exact test).
Both Env and Gag response rates were significantly greater than
the Pol response rate (p=0.001 and p=0.003 respectively; Fisher’s
exact test). Eleven of the Gag responders and all of the Pol
responders were also Env responders. While a dose-dependence of
the response was evident in both routes with the high-dose IM group
response rate (90%) . the low-dose IM group response rate (40%),
and the high-dose ID group response rate (60%) . the low-dose ID
group response rate (30%), these differences were not statistically
significant. The durability of the Elispot responses was reflected in
the observation that 6/22 responding subjects had positive Elispot
responses at all 4 post-vaccination time-points and 15/22 were still
positive at 252 days post-vaccination. The magnitude of the HIV-
specific IFNc Elispot response was low (corrected SFC/10
6 PBMC
range=27–628) (see supplementary Figure S2). The highest
median HIV-specific Elispot response for any time-point post-
vaccination was detected in the high-dose IM group at 252 days
post-vaccination (median corrected SFC/10
6 PBMC=78). For the
route comparison groups (IM and ID 10
7 pfu) there was no
difference statistically in the median Elispot responses at any time-
point post-vaccination, although the IM group response exceeded
the ID group at all time-points. However, greater Elispot responses
were detected at days 42 and 98 post-vaccination initiation (Mann-
Whitney test; p=0.027 and p=0.005 respectively) in the combined
IM groups with respect to the combined ID groups, but this
difference was not significant at days 168 and 252 post-vaccination.
One pre-vaccination sample and no placebo recipients had
detectable IFNc Elispot positive responses. The anti-vector (MVA
backbone)IFNcElispotresponsesshoweda90%cumulativepositive
response rate in the IM groups, while the ID groups showed 90%
and 30% in the high-dose and low-dose vaccine recipients
respectively.
Lymphocyte proliferation assay. LPA responses are shown
in Figure 3. Responses were assessed at one pre-vaccination time-
point and one post-vaccination time-point (Day 252; 6 months post
the 3
rd and final vaccination). Lymphoproliferative responses
against the HIV antigens were detected in all study groups with
100% (9/9) of vaccinees responding to rgp140 in both IM groups.
Responses were predominantly Env-directed with a significantly
higher response rate to rpg140 compared with rp24 in the
combined IM groups (p=0.001; Fisher’s exact test), and a non-
significant trend for higher rgp140 response rates in the combined
ID groups (Figure 3, panels A and B). While there were no
differences in response rates or magnitude between doses within the
two routes, there was a route-dependence of the response.
Comparing the rgp140 responses between the two routes a
statistically significant higher response rate (p=0.003; Fisher’s
exact test) and magnitude (p=0.001; Mann-Whitney test) was
observed for the combined IM groups versus the combined ID
groups. This statistical difference in magnitude of response
(p=0.001, Mann-Whitney test) was retained in a direct
comparison of the high-dose ID and low-dose IM groups (both
received 10
7 pfu per vaccination). Aldrithiol-2 inactivated WIV
isolates CM235WIV and MNWIV were used to test for responses
against the total insert gene products and for cross-reactivity of the
Phase I HIV Vaccine Study
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against CM235WIV were greatest in the IM groups (9/9 and 7/9 for
low- and high-dose respectively) and lower in the ID groups (7/9
and 5/8 for low- and high-dose respectively), although this
difference was not statistically significant. Again, a route-
dependence in the magnitude of the proliferative response against
CM235WIV was observed with the low-dose IM LSI significantly
higher than the high-dose ID LSI (p=0.012, Mann-Whitney test).
The MNWIV responses mirrored the CM235WIV responses in both
frequency and magnitude with no statistically significant differences
in the frequency or magnitude of responses. Collectively, these data
demonstrate that vaccination with MVA-CMDR induces a potent
insert-directed proliferative response that is route-dependent and
cross-reactive between CRF01_AE and subtype B HIV-1 isolates.
Whole blood ICS. The whole blood ICS assay results are
shown in Table 4 including data from one pre-vaccination time-
Figure 2. Systemic and local vaccine related reactogenicity for each dose and route of vaccination. The number and percent of subjects
experiencing one or more local (panel A) or systemic (panel B) reactions is shown for each group after stratification by severity. The most severe
reaction experienced by a volunteer determined the stratification into none, moderate, mild or severe categories. No serious or life threatening
adverse events were reported.
doi:10.1371/journal.pone.0013983.g002
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no responses to the HIV antigens pre-vaccination. Most volunteers
responded to the HIV antigens at one time point and in only a few
cases were the responses sustained (positive at 2–3 different time
points). Responses were predominantly CD4
+ T cells and directed
against the Env peptide pool (range for CD4
+ Env responses
0.051–0.400, CD8
+ Env 0.058–0.180, CD4
+ Gag 0.054–0.170,
CD8
+ Gag 0.08–0.210). The data shown in Table 4 represent any
responses to the 92THO23 Env peptide pool (Env) and CM240
Gag peptide pool (Gag) at any time post-vaccination. There was a
significant route-dependence of the CD4
+ T cell response with a
higher rate of responders in the combined IM groups versus the
combined ID groups (p=0.01, Fisher’s exact test). No significant
dose-dependence of the response was observed, although a trend
toward a higher number of positive responders was observed in the
higher dose of both routes. CD8
+ T cell responses were much more
sporadic among the four groups, with too few responses to discern a
route- or dose-dependence of the response. These data show that
MVA-CMDR was immunogenic eliciting predominantly CD4
+
responses as measured by IL-2 and IFNc gene up-regulation and
protein production.
Qualitative analysis of the combined cellular assays. In
order to perform a statistically robust analysis of the dose- and
route-dependence of the responses generated by MVA-CMDR,
the qualitative response data for the
51Cr-release, Elispot,
lymphocyte proliferation and whole blood ICS assays were
combined and analyzed for differences to placebo and trends in
dose and route responsiveness. For this analysis the cumulative
number of post-vaccination responders for each of the four assays
were summed for each dose and route group. Figure 4 shows the
cumulative qualitative post-vaccination response data stratified by
route and dose for Env and Gag (or Gag/Pol responses for the
51Cr-release assay). Compared with the placebo group all routes
and doses showed a significantly increased response to Env
antigens post-vaccination, while all but the lowest dose ID group
showed a significantly increased Gag response (Fisher’s exact test).
For both Env and Gag a significant trend was observed (p=0.001
for Env; p=0.009 for Gag/Pol; x
2 trend test) with the qualitative
response rates following the ensuing ranking: high-dose IM (10
8
pfu).low-dose IM (10
7 pfu).high-dose ID (10
7 pfu).low-dose ID
(10
6 pfu). Collectively, these data demonstrate that 10
8 pfu IM is
the most immunogenic dose and route of administration for
induction of cellular immune responses by MVA-CMDR.
Multi-functional flow cytometry (MFC) assay. Responses
were evaluated at one pre-vaccination time-point and one post-
vaccination time-point (the predicted peak of immunogenicity Day
98; 2 weeks post the 3
rd vaccination) in the high- and low-dose IM
groups and the high-dose ID group (30 vaccinees and 6 placebos).
The gating strategy for the multiparameter flow cytometry is
shown in supplementary Figure S3. Overall responses were
predominantly to the Env peptide pool and CD4
+ T cell mediated
(22/30 Env responders versus 11/30 Gag responders by any single
cytokine/function). Table 5 summarizes the responses against the
Env peptide pool in each of the three groups tested. Responses
against the Env peptides were dose and route-dependent: high-
dose IM (10/10).low-dose IM (7/10).high-dose ID (5/10). In
the high-dose IM group 100% of vaccine recipients exhibited
CD4
+ T cells producing IFNc in response to the Env peptide pool.
Eight of these 10 volunteers also responded to Env peptides by
producing IL-2, and of these 4 volunteers also produced TNFa (1
volunteer exhibited production of MIP-1b in addition to the three
cytokines). In the IM vaccine recipients IFNc, TNFa and IL-2
dominated the CD4
+ T cell response. Env-specific CD8
+ T cells
were detected in 3 volunteers – all in the high-dose IM group - and
all exhibited CD107a surface translocation. Gag-specific CD4
+ T
cells were detected in 3 volunteers in each of the IM vaccine
groups and 2 volunteers in the high-dose ID group. No Gag-
specific CD8
+ T cell responders were identified with this assay. A
Table 2. Cross-sectional frequency of positive CD8 CTL responses as measured in the
51Cr-release assay.
Dose/Route** Antigen*** Pre-Vacc Day 42 Day 98 Day 168 Day 252 Cumulative
(N) 0 (2 Wks post 2
nd) (2 Wks post 3
rd) (12 Wks post 3
rd) (24 Wks post 3
rd) Any Post-Vacc
Env 0/9 3/10 2/10 2/6 4/9 6/10 (60%)
10
8 pfu IM Gag 0/9 1/10 1/10 1/6 1/9 4/10 (40%)
(10) Any 0/9 3/10 2/10 2/6 5/9 7/10 (70%)
Env 0/5 4/8 1/8 0/10 1/9 5/10 (50%)
10
7 pfu IM Gag 0/5 0/8 1/8 2/10 1/9 2/10 (20%)
(10) Any 0/5 4/8 2/8 2/10 1/9 6/10 (60%)
Env 0/6 1/9 1/9 3/6 3/8 5/9 (56%)
10
7 pfu ID Gag 0/6 0/9 0/9 2/6 1/8 2/9 (22%)
(9) Any 0/6 1/9 1/9 4/6 3/8 5/9 (56%)
Env 0/5 2/8 1/8 1/6 2/7 6/9 (67%)
10
6 pfu ID Gag 0/5 0/8 0/8 0/6 0/7 0/9 (0%)
(9) Any 0/5 2/8 1/8 1/6 2/7 6/9 (67%)
Env 0/5 0/5 0/6 1/4 0/4 1/7 (14%)
Placebo Gag 0/5 0/5 0/6 0/4 0/4 0/6 (0%)
(7) Any 0/5 0/5 0/6 1/4 0/4 1/7 (14%)
*The number of positive responders for each antigen at each time-point tested for each vaccination group (by route and dose) is shown. The determination of a positive
response used is outlined in the Materials and Methods section. Cumulative analysis represents a positive response at any time-point post-vaccination. Responses were
measured pre-vaccination, 2 weeks post-2
nd vaccination, 2 weeks post-3
rd vaccination and 12 and 24 weeks post-3
rd vaccination.
**Numbers in parentheses represent the total subjects tested per group.
***Responses are shown for single recombinant MVA vectors expressing the Env and Gag/Pol inserts in the double recombinant MVA-CMDR vaccine product.
doi:10.1371/journal.pone.0013983.t002
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subjects who were tested. Figure 5 shows the cumulative
multifunctional analysis of the T cell responses detected against
the Env peptide pool in the high-dose IM group. Responding
CD4
+ T cells were mono-functional (23%), dual functional (45%)
or tri-functional (28%) producing IL-2, TNFa and/or IFNc, while
the CD8
+ T cells were mono-functional (41%) and dual functional
(39%), producing MIP-1b and translocated CD107a and/or
produced IFNc. The profiles of the Env- and Gag-specific CD4
+
T cells were similar.
Humoral Immunogenicity
Binding antibodies. Volunteers were assessed for the
presence of binding antibodies against HIV-1 CM243 gp120,
HIV-1 IIIB p24 and the vector itself (anti-vaccinia antibodies) at
three time-points – pre-vaccination, and 2 weeks and 6 months
post-completion of the vaccination schedule (days 98 and 252; 2
weeks and 6 months post 3
rd vaccination respectively). Table 6
summarizes the quantitative (GMT for each group) and qualitative
analyses for the binding antibody responses. Binding antibodies
against gp120 were generated in up to 90% of vaccine recipients
(9/10 IM high dose) after 3 doses of MVA-CMDR. Binding
antibodies against p24 were generated in 90–100% of vaccine
recipients regardless of the route after 3 doses of MVA-CMDR.
Quantitatively, the median GMTs for both gp120 and p24
antigens displayed a peak at 2 weeks post-completion of
vaccination and a decline by 6 months post-vaccination. There
was a statistically significant difference (p,0.05; Kruskal-Wallis
test with Dunn’s correction for multiple comparisons) in median
GMT between both IM groups and the placebo group for gp120
and p24 at Day 98, but this difference was maintained only for the
high-dose IM group at day 252. In the ID route this quantitative
statistical difference held only for high-dose ID group at day 98.
For both HIV antigens, the GMTs generated by the IM route
exceeded the ID route quantitatively at both post-vaccination
time-points. This difference was statistically different only when
comparing the IM groups with low-dose ID group (p,0.05;
Kruskal-Wallis test with Dunn’s correction for multiple
comparisons). Of note was the observation that all treatment
groups showed a quantitative decrease in binding antibody GMTs
at 6 months post-vaccination compared with 2 weeks post-
vaccination (p=0.02 for all groups; Wilcoxon ranked sign test).
Qualitatively the diminution of antibody response rates by 6
months post-vaccination was most evident for gp120, but was also
observed for vaccinia virus response rates. Anti-vaccinia binding
antibodies were generated in 90–100% of vaccine recipients
Table 3. Cross-sectional vaccine responsiveness as measured by the Interferon-c Elispot assay*.
Dose/Route** Antigen*** Pre-Vacc Day 42 Day 98 Day 168 Day 252 Cumulative
(N) 0
(2 Wks post
2
nd)
(2 Wks post
3
rd)
(12 Wks post
3
rd)
(24 Wks post
3
rd) Any Post-Vacc
Quantitative analysis: Median[Range] SFC/10
6 PBMC****
E n v 0 56659 ( 9 0 % )
10
8 pfu IM Gag 0 2 3 2 2 4 (40%)
(10) Any 0 6 6 7 6 9 (90%)
Quan. 3 [0–20] 57 [0–337] 71 [5–279] 66 [24–270] 78 [0–317]
E n v 0 23344 ( 4 0 % )
10
7 pfu IM Gag 0 2 3 3 2 4 (40%)
(10) Any 0 3 4 4 4 4 (40%)
Quan. 4 [0–11] 19 [1–241] 20 [3–224] 19 [3–511] 19 [1–632]
E n v 1 22124 ( 4 0 % )
10
7 pfu ID Gag 0 0 1 2 3 4 (40%)
(10) Any 1 2 2 2 4 6 (60%)
Quan. 11 [0–30] 17 [0–55] 12 [0–90] 53 [1–97] 44 [0–138]
E n v 0 11213 ( 3 0 % )
10
6 pfu ID Gag 0 0 1 1 1 1 (10%)
(10) Any 0 1 1 2 1 3 (30%)
Quan. 2 [0–8] 2 [0–38] 7 [0–119] 4 [0–145] 7 [0–99]
E n v 0 00000 ( 0 % )
Placebo Gag 1 0 0 0 0 0 (0%)
(8) Any 0 0 0 0 0 0 (0%)
Quan. 6 [0–82] 3 [0–23] 1 [0–21] 5 [0–48] 6 [0–57]
*The number of positive responders for each antigen at each time-point tested for each vaccination group (by route and dose) is shown. The cut-off for a positive
response was 27 SFC/10
6 PBMC. Cumulative analysis represents a positive response at any time-point post-vaccination. Responses were measured pre-vaccination, 2
weeks post-2
nd vaccination, 2 weeks post-3
rd vaccination and 12 and 24 weeks post-3
rd vaccination.
**Numbers in parentheses represent the total subjects tested per group.
***Responses are shown for Env and Gag peptide pools representing the vaccine inserts and also for responders to any insert-derived peptide pool. Only 2 responders
were detected using the polymerase (Pol) peptide pool (1 in the 10
8 pfu IM group and 1 in the 10
7 pfu ID group).
****Values for the quantitative analysis represent the corrected data values (test antigen - background). The median value [with range] for the summed responses
(Env+Gag+Pol) is shown as SFC/10
6 PBMC.
doi:10.1371/journal.pone.0013983.t003
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base-line anti-vaccinia binding antibody responses were negative
in all groups. At the 10
7 pfu dose the IM and ID routes
demonstrated qualitative and quantitative equivalency for
generating anti-vaccinia binding antibodies. The anti-vaccinia
binding antibodies showed a quantitative decrease by 6 months
post-vaccination for all treatment groups as observed for the HIV
antigens. Overall, the 10
8 pfu dose delivered by the IM route was
superior for generating binding antibodies against all three
antigens tested.
ADCC activity. Volunteers were assessed for ADCC activity
at two time-points: pre-vaccination; and 2 weeks post-vaccination
(day 98). MVA-CMDR vaccination elicited modest ADCC
activity as shown in Table 7, with the greatest frequency of
responders to both CRF01_AE (40%) and subtype B gp120 (30%)
observed in vaccinees receiving the highest dose (10
8 pfu IM). The
median (inter-quartile range) %RL in this group to CRF01_AE
and MN gp120 was 16.5% (5.0–42.6) and 8.8% (7.0–28.0),
respectively, compared to 10.6% (3.6–19.3) and 2.8% (2.0–4.2)
respectively, in the placebo group.
Figure 3. Lymphocyte proliferation responses for each dose and route. Lymphocyte proliferation responses against recombinant proteins
(TH023 gp140 and LAI p24) are shown for all doses and routes of vaccination (panels A and B). HIV whole inactivated virus (WIV) antigens CM235WIV
(CRF01_AE vaccine matched isolate) and MNWIV (subtype B heterologous isolate) are shown for all doses and routes of vaccination in panels C and D
respectively. The Y-axis represents the LSI (scale=log2) and the dotted line designates an LSI of 5 (cut-off for positive responses). Blue and red circles
represent pre- and post-vaccination (day 0 and day 252) samples respectively.
doi:10.1371/journal.pone.0013983.g003
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MVA-CMDR was safe and well tolerated at all dosages and
routes tested. There were no serious adverse events related to the
vaccine and there was no evidence of cardiac toxicity. MVA-
CMDR elicits a modest, yet readily detectable cellular immune
response against the HIV insert gene products in most vaccine
recipients. Using traditional assay platforms, such as lymphocyte
proliferation or chromium release assays, up to 100% of the
volunteers had detectable lymphoproliferative responses (depend-
ing upon dose and route) and two-thirds (63%) had CD8-
dependent CTL activity depending upon the dose and route.
These data are consistent with the priming of both CD4
+ and
CD8
+ T cells. Using more sophisticated flow cytometry-based
assay techniques the balance and frequency of the cellular immune
response is further elucidated. CD4
+ T cells, in particular those
targeting the Env protein, were most frequently detected with both
whole blood ICS and multi-functional ICS. The high-dose IM
vaccination regimen resulted in the induction of CD4
+ T cells
targeting Env in almost all volunteers using both ICS assays.
However, CD8
+ T cells specific for Env were detected in only 30%
of the same volunteers using the two assay platforms. The whole
blood ICS assay appeared to be more sensitive for detecting Gag-
specific CD8
+ T cells – 40% versus no positive responses with the
multifunctional assay in the high-dose IM group. This observation
may represent an important qualitative difference in sensitivity
between the two assay platforms. The detection of Env-specific
CD4
+ T cells that synthesized IL-2, IFNc and TNFa by flow
cytometry is consistent with the lymphocyte proliferation data.
The sporadic detection of insert-specific CD8
+ T cells by
51Cr-
release and flow cytometry is consistent with the induction of a low
frequency of CD8
+ T cells with high proliferative capacity. The
durability of the cellular immune response is reflected in the 100%
lymphoproliferative response rates in both IM route groups to the
TH023 recombinant protein at 6 months after completion of the
vaccination schedule and in the detection of Elispot positive
responses at the same time-point. Overall, Env was consistently the
predominant target of the cellular immune response and CD4
+ T
cells were the most frequently detected responder cell type. A dose
and route effect of the vaccination procedure was observed with
the high-dose (10
8 pfu) IM route of vaccine delivery being the most
immunogenic.
The observed trend towards elicitation of numerically greater
CD4
+ T cell responses targeting HIV-1 Envelope by the vaccine is
an important observation. In humans, the use of recombinant
multigenic MVA as a vector for both priming and boosting
immune responses appears to be similar to multigenic DNA
vaccines, which also induce primarily CD4
+ T cell responses
against Env-derived gene products [17,18,19,20]. Both the present
study and the EV02 study of a NYVAC-C vaccine product by the
EuroVacc Consortium suggest that vaccination with vaccinia-
derived poxvirus vectors may be equivalent in their ability to
induce predominantly Env-specific CD4
+ T cells with multigenic
products [20]. While canarypox-based vaccines have been shown
to induce CD4
+ T cells responses against Envelope antigens in a
multigenic canarypox-prime and protein-boost setting, it is as yet
unclear whether the phenomenon of Env-specific CD4
+ T cell
dominance can be generalized to all multigenic poxvirus vectors
[5,21,22]. In contrast, adenovirus-based vectors used either as a
prime and boost, or as a boost for a DNA vaccine prime, appear to
generate higher levels of cellular immune responses in general and
generate a better balance of CD4
+ and CD8
+ T cell responses to
multiple gene products in a multigenic setting [12,23,24]. While
studies performed in the setting of HIV-1 infection have shown
that robust, polyfunctional CD8
+ T cell responses targeting
multiple epitopes in the Gag (and in some cases Nef) protein are
associated with better clinical outcome and protection from disease
progression it is unclear whether such cells would also provide
protection from infection [4,25,26,27,28]. In fact, in the setting of
a vaccine that induced Gag- and Nef-specific CD4
+ and CD8
+ T
cell responses no protection from HIV-infection was conferred
[29,30]. Hence, the functional relevance of Env (and Gag) specific
CD4
+ and CD8
+ T cells in setting of vaccination for prevention of
infection needs to be further explored. In particular, subtle
differences in the qualities of T cells generated in response to
different vector-based delivery combinations of multigenic gene
Table 4. Cross-sectional vaccine responsiveness by Whole Blood ICS assay*.
Dose/Route** Antigen*** Pre-Vacc Day 42 Day 98 Day 168 Day 252 Cumulative
(N) 0
(2 Wks post
2
nd)
(2 Wks post
3
rd)
(12 Wks post
3
rd)
(24 Wks post
3
rd) Any Post-Vacc
CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8
10
8 p f u I M E n v 00506031539 ( 9 0 % ) 3 ( 30%)
( 1 0 ) G a g 00302020003 ( 3 0 % ) 0 ( 0 % )
10
7 p f u I M E n v 00502011106 ( 6 0 % ) 1 ( 10%)
( 1 0 ) G a g 00323121024 ( 4 0 % ) 4 ( 40%)
10
7 p f u I D E n v 10102131115 ( 6 2 % ) 3 ( 33%)
( 9 ) G a g 00001011002 ( 2 2 % ) 1 ( 11%)
10
6 p f u I D E n v 00001000001 ( 1 1 % ) 0 ( 0 % )
( 9 ) G a g 00101001001 ( 1 1 % ) 1 ( 11%)
Placebo Env 1 0 000021102 ( 2 5 % ) 1 ( 13%)
( 8 ) G a g 00000000010 ( 0 % )1 ( 13%)
*The cut-off for a positive response was 36over background and . or equal to 0.05%.
**Numbers in parentheses represent the total subjects tested per group. One volunteer in the 10
6 pfu ID group did not have data for 2Wks post 2nd and 2 Wks post 3rd
and one placebo is missing data for 24 Wks post 3rd. For this reason the subject count may vary from visit to vist.
***Responses are shown for Env and Gag peptide pools representing the vaccine inserts. See material and methods for more details.
doi:10.1371/journal.pone.0013983.t004
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generate T cells that either help appropriate antibody class
switching and affinity maturation, or act as direct effector cells, or
both, will be a critical quality of any effective HIV vaccine.
Binding antibody responses were detected against both p24 and
gp120. A clear dose- and route-dependence of the binding
antibody response was evident with the IM routes being most
immunogenic. Antibody titers peaked two-weeks after vaccination
and waned, but were still detectable at 6 months post-vaccination.
The diminution of binding antibody GMTs in the interim between
2 weeks and 6 months post-vaccination completion may be
important with respect to poxvirus vectors in general. In the
ALVAC-HIV/AIDSVAX B/E Phase III trial (RV144) the modest
protective efficacy appeared be transient during the 6 months
immediately post-vaccination and then waned. If induction of
transient antibody responses is typical of non-replicating poxvirus
vectors in general then strategies that increase the durability of
such responses will need to be established. MVA-CMDR would
therefore be an ideal candidate for testing different prime/boost
strategies that will increase the durability of antibody responses.
These antibodies likely had functional capacity as measured by
ADCC activity in four volunteers in the high-dose IM group
following three immunizations with MVA-CMDR. Previously, 4
immunizations with canarypox (vCP1521) expressing CRF01_AE
gp120 had failed to induce ADCC activity [16], implying that
MVA-CMDR is a more potent inducer of ADCC than canarypox
vectors expressing CRF01_AE antigens. It is unknown whether
such antibody responses would, on their own, be sufficient to
mitigate transmission or to reduce viral set point and/or modulate
disease progression.
Compared with other stand alone MVA-based HIV vaccine
products MVA-CMDR would appear to be at least as immuno-
Figure 4. Cumulative analysis of all qualitative cellular immune response assays. The number of positive responders for HIV antigens (Env
or Gag) in the
51Cr-release, Elispot, lymphocyte proliferation and whole blood ICS assays was tallied for all groups and compared with the placebo
recipients. The figure graphically displays the summed cumulative positive responders for each of the 4 assay platforms. The total number of tests
performed in each group is denoted below the dose and route. The top and bottom tables summarize the statistical analyses for Env and Gag
respectively.
doi:10.1371/journal.pone.0013983.g004
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products (at a 2.5 fold lower dose than either) and substantially
more immunogenic than the HIVA vaccine product [33]. MVA-
CMDR also appears to be at least as immunogenic as the related
attenuated poxvirus vector NYVAC product vP2010 [17]. For
HIV and other infectious diseases, it has become increasing
commonplace to use rMVA and NYVAC products to augment
DNA primed cellular and humoral responses [20,34,35]. MVA-
CMDR has been shown previously to be an effective boost for
cellular immune responses generated by a heterologous DNA
vaccine prime [9]. When used as stand-alone products recombi-
nant poxvirus vectors induce quantitatively lower insert-directed
Figure 5. Multifunctional flow cytometry analysis for HIV Env-specific T cells. Analysis was based on the cumulative positive cells in all
Boolean subsets for all volunteers who were scored as positive by single cytokine analysis in the high-dose (10
8 pfu) intra-muscular vaccine recipients
(Table 5). The legend shows the Pie Chart arcs representing each cytokine (or function). Pie Chart wedges show the relative sizes of the subsets of
cells expressing the combination of functions represented in the surrounding Pie chart arcs.
doi:10.1371/journal.pone.0013983.g005
Table 5. Multi-Functional Flow Cytometry Results (Env peptide pool responses)*.
Dose/Route** N CD4
+ T cells Env responses CD8
+ T cells Env responses
CD107a IFNc MIP-1a IL-2 TNFa CD107a IFNc MIP-1b IL-2 TNFa
10
7 p f u I M 1 0 P r e 00 1 0 0 2 0 0 00
D a y 9 8 1 30661 001 1
Median% 0.02 0.03 0.06 0.05 0.02 0 0.04
[Range] [0.02] [0.02–0.09] [0.05–0.24] [0.03–0.24] [0.02] [0.03] [0.04]
10
8 p f u I M 1 0 P r e 00 1 1 0 0 0 1 00
D a y 9 8 1 1 0 2843 321 1
Median% 0.02 0.06 0.025 0.09 0.09 0.05 0.04 0.26 0 0.04
[Range] [0.02] [0.03–0.14] [0.02–0.03] [0.06–0.17] [0.05–0.16] [0.03–0.23] [0.02–0.07] [0.07–0.46] [0.04] [0.03]
10
7 p f u I D 1 0 P r e 01 1 0 1 1 1 0 00
D a y 9 8 0 41422 100 0
Median% 0.03 0.04 0.04 0.03 0.09 0.03
[Range] [0.02–0.05] [0.04] [0.02–0.04] [0.03–0.04] [0.02–0.15] [0.03]
*The number of positive responses for each function is shown (bolded) as measured at 2 weeks after the third vaccation (day 98). The quantitative values (median and
range) represent the corrected value (test antigen - background) for the responses scored as positive.
**6 placebo recipients were tested in the same assay procedure with a two false positives scored for CD107a (one CD4
+ and one CD8
+) at a pre-vaccination visit.
doi:10.1371/journal.pone.0013983.t005
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rus-based vectors [12,23,30,36]. Their continued use as HIV
vaccine modalities is likely to be contingent upon: (i) successful
pairing with other vectors in prime-boost regimens to increase the
magnitude of the immune response; (ii) verification that the
immune responses generated are qualitatively different to those
generated by alternative vectors and (iii) successful demonstration
of vaccine-induced protection in primate lentivirus challenge
models.
MVA-CMDR was designed to be administered in combination
with other vaccine products - either as the prime for a prime/boost
poxvirus followed by recombinant protein vaccine schedule, as
performed in the recently completed RV144 trial, or in
combination with other vaccines such as DNA-based or
Adenovirus-based HIV vaccines. Given that DNA-prime and
MVA-boost vaccinations are superior to MVA alone vaccinations
in animal models and in human trials [33,34,37,38,39], and the
fact that MVA-CMDR has already been used successfully to boost
a heterologous DNA-based vaccine product in humans [9] it is
likely that this product will prove useful as a boost for cellular
responses induced by other heterologous priming modalities. In
addition, the versatility of MVA-CMDR may be further explored
by exploiting its capacity to prime for antibody responses in
prime/boost strategies that further test the concepts arising from
the RV144 trial [5].
Supporting Information
Figure S1 Cumulative CD8-dependent CTL responses. Cumu-
lative responses determined by the
51Cr-release assay are shown
for HIV-specific (any Env/Gag/Pol) responses (panel A) and for
vector-specific (MVA) responses (panel B). The y-axis represents
the cumulative response rate in percentage for each route and
dose, while the time post-vaccination initiation (days) is shown on
the x-axis. Red arrows denote the timing of the vaccination series.
Found at: doi:10.1371/journal.pone.0013983.s001 (0.03 MB
PDF)
Figure S2 Quantitative IFNc Elispot responses for all doses and
routes. Elispot counts are shown for the total peptide response
(Env plus Gag plus Pol responses; panels A and B), for the Env
peptide response (panels C and D) and the Gag peptide response
(panels E and F). Panels A, C and E show the intra-muscular
vaccination responses, while panels B, D and F show the intra-
dermal vaccination responses. The y-axis represents the magni-
tude of the response (IFNc SFC/10
6 PBMC), while the time post-
vaccination initiation (days) is shown on the x-axis. Data is
presented as corrected values (test article - background). The
dotted line (27 SFC/10
6 PBMC) represents the limit of detection
for the validated ELISPOT assay and the red arrows denote the
timing of the vaccination series.
Found at: doi:10.1371/journal.pone.0013983.s002 (0.10 MB
PDF)
Figure S3 Gating strategy applied to the multifunctional flow
cytometric analyses. A representative sample is shown for the
gating strategy used for viable, CD3+ lymphocyte identification
and subsequent subdivision into CD4+ and CD8+ T cells (panel
A). A functional positive response is shown for both CD4+ T cells
(IL-2 and TNFa) and CD8+ T cells (CD107a and MIP-1b)i n
response to the CM235 Env peptide pool (panel B).
Found at: doi:10.1371/journal.pone.0013983.s003 (0.22 MB
PDF)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0013983.s004 (0.75 MB
PDF)
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0013983.s005 (0.23 MB
DOC)
Table 6. Geometric Mean Antibody Titers and Response Frequency to HIV Proteins and Vaccinia*.
Dose/Route N HIV-1 gp120 (CM243) HIV-1 p24 (IIIB) Vaccinia Virus
GMT (No. of Responders) GMT (No. of Responders) GMT (No. of Responders)
Pre-vacc
2 weeks
post 3
rd
vacc
6 months
post 3
rd
vacc Pre-vacc
2 weeks
post 3
rd
vacc
6 months
post 3
rd
vacc Pre-vacc
2 weeks
post 3
rd
vacc
6 months
post 3
rd
vacc
10
6 pfu ID 10 39 (0/10) 57 (2/10) 30 (0/10) 26 (1/10) 299 (9/10) 65 (5/8) 50 (0/10) 186 (9/10) 67 (2/10)
10
7 pfu ID 10 57 (2/10) 208 (7/10) 43 (1/10) 31 (2/10) 1343 (9/10) 109 (9/10) 50 (0/10) 657 (9/10) 66 (2/10)
10
7 pfu IM 10 38 (1/10) 354 (8/10) 54 (1/10) 29 (1/10) 2907 (10/10) 434 (10/10) 50 (0/10) 543 (9/10) 111 (6/10)
10
8 pfu IM 10 69 (3/10) 787 (9/10) 102 (4/10) 26 (0/10) 3427 (10/10) 412 (10/10) 50 (0/10) 2071 (10/10) 195 (9/10)
Placebo 8 44 (1/8) 29 (0/8) 34 (1/7) 29 (1/8) 29 (1/8) 25 (0/7) 50 (0/8) 50 (0/8) 50 (0/8)
*The cut-off for determining a positive response was the upper 99% confidence limit of the end-point titers for all pre-vaccination samples for each antigen.
Note: Responses were measured at one pre-vaccination time-point (Pre-vacc), the presumed peak of immunogenicity (2 weeks post 3
rd vaccination; Day 98) and tested
for durability (6 months post 3
rd vaccination; Day 252).
doi:10.1371/journal.pone.0013983.t006
Table 7. Cumulative frequency of post-vaccination positive
ADCC responses.
Dose/Route N CRF01_AE gp120* Subtype B gp120*
10
6 pfu ID 9 0 (0%) 1 (11%)
10
7 pfu ID 9 1 (11%) 2 (22%)
10
7 pfu IM 10 1 (10%) 2 (20%)
10
8 pfu IM 10 4 (40%) 3 (30%)
Placebo 8 1 (12%) 1 (12%)
*Positive ADCC responses to CRF01_AE and subtype B gp120 proteins based on
a cut-off of the 90th percentile relative lysis in the placebo group.
doi:10.1371/journal.pone.0013983.t007
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